How Has CymaBay Therapeutics Performed Financially?
CymaBay Therapeutics’ (CBAY) MBX-2982 is under evaluation as a novel therapeutic agent. The company has yet to disclose its target indication. The drug was synthesized as a GPR119 agonist and is shown to increase glucose-dependent insulin secretion in animal models and in vitro. Non-clinical studies have shown MBX-2982 to have desirable effects on blood glucose levels.